📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-24 20:03
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Archit Organosys Withdraws 67.44% Acquisition of Archit Life Science and Preferential Issue
Archit Organosys has issued a corrigendum to its FY 2025-26 Annual Report, withdrawing three major agenda items from its upcoming AGM notice. Management dropped Item 8 (increase in authorized share capital), Item 9 (acquisition of up to 67.44% stake in Archit Life Science Limited as a material related-party transaction), and Item 10 (preferential issue of equity shares for consideration other than cash). Consequently, the related-party acquisition and dilution via preferential allotment will not be tabled for shareholder vote.
Confidence: HIGH
What changedManagement cancelled AGM resolutions to acquire a 67.44% stake in Archit Life Science and issue preferential equity shares to finance it.
Why it mattersCancels significant equity dilution and an intra-group material related-party transaction, keeping the existing share capital structure unchanged for now.
Withdrawn Stake Acquisition: 67.44%Shares in Target Company: 1,36,24,172Proposed Sec 186 Limit Increase: Rs. 400.00 CroresFY26 Revenue (Annual Report): Rs. 14,383.71 Lakhs
📅 Short termRemoves immediate overhang of dilution from the non-cash preferential allotment, though raises governance questions on why the deal was abruptly withdrawn.
📈 Long termHalts the consolidation of Archit Life Science under Archit Organosys; future capital allocation strategy will depend on alternative expansion plans.
⚠ Risk flags
- Related-party transaction restructuring uncertainty
- High Section 186 loan/guarantee limit sought (Rs 400 Cr vs Rs 77 Cr net worth)
Key Highlights
Withdrawn acquisition of up to 1,36,24,172 equity shares (67.44% stake) of M/s Archit Life Science Limited
Withdrawn preferential allotment of equity shares for consideration other than cash
Withdrawn proposal to increase Authorized Share Capital and alter Memorandum of Association
Separate resolution to increase Section 186 loan/guarantee limits from Rs 100.00 Cr to Rs 400.00 Cr remains on the agenda
👀 What to Watch
Track management commentary regarding why the acquisition was called off and monitor voting outcomes on the Section 186 limit hike to Rs 400 Cr.
Archit Organosys Withdraws Acquisition of 67.44% Stake in Archit Life Science from AGM Agenda
Archit Organosys Limited has issued a corrigendum to its 33rd Annual General Meeting notice scheduled for September 30, 2026, officially withdrawing three key resolutions. The withdrawn items include the acquisition of up to 1,36,24,172 equity shares (67.44% stake) in Archit Life Science Limited as a material related-party transaction, the associated preferential share issue (other than cash), and an increase in authorized share capital. However, resolutions regarding related-party transactions (advancing loans up to ₹75 crore and material supply up to ₹100 crore) and increasing Section 186 loan/investment limits to ₹400 crore remain on the agenda.
Confidence: HIGH
What changedThe company dropped resolutions to acquire a 67.44% controlling stake in Archit Life Science via a preferential share swap and the corresponding capital expansion.
Why it mattersThe acquisition would have significantly altered the company's asset base and capital structure; its sudden withdrawal puts the strategic consolidation on hold, leaving large proposed inter-corporate loan limits intact.
Withdrawn acquisition stake: 67.44%Shares in withdrawn acquisition: 1,36,24,172Proposed RPT loan limit per FY: Rs. 75.00 CroreProposed RPT trading limit per FY: Rs. 100.00 CroreProposed Sec 186 investment/loan limit: Rs. 400.00 Crore
📅 Short termRemoves immediate overhang and potential dilution from a preferential equity issue, but raises questions regarding capital allocation strategy.
📈 Long termStructural consolidation is paused; investors should monitor corporate governance given significant remaining related-party lending proposals exceeding net worth (₹77 Cr).
⚠ Risk flags
- High related-party transactions (loan limits up to ₹75 Cr vs company net worth of ₹77 Cr)
- Sudden withdrawal of major M&A and capital restructuring agenda days before AGM
Key Highlights
Item No. 9 withdrawn: Acquisition of up to 1,36,24,172 shares (67.44% equity) of Archit Life Science Limited cancelled from AGM agenda
Item No. 8 & 10 withdrawn: Increase in Authorized Share Capital and preferential share issuance (other than cash) dropped
Remaining Agenda Item 5: Proposed loan advances up to ₹75.00 crore and supply of goods up to ₹100.00 crore per year for FY27 and FY28 with Archit Life Science
Remaining Agenda Item 7: Proposed increase in limits under Section 186 from ₹100.00 crore to ₹400.00 crore
AGM to proceed via VC/OAVM on September 30, 2026, including dividend consideration of Re. 1/- (10%) per share
👀 What to Watch
Track the AGM voting results on September 30, 2026, and watch for management commentary or exchange disclosures regarding why the acquisition was cancelled and whether the related-party funding plans remain intact.
Archit Organosys Withdraws AGM Agendas to Acquire 67.44% Stake in Archit Life Science
Archit Organosys has approved the withdrawal of three key agenda items from its upcoming AGM on September 30, 2026. The withdrawn resolutions included the acquisition of up to 1,36,24,172 equity shares (a 67.44% stake) in Archit Life Science Limited as a Material Related Party Transaction, along with a related increase in authorized capital and a preferential issue of shares (other than cash). Management decided to withdraw the preferential issue in its current form to restructure the transaction. The company stated this withdrawal is not expected to adversely impact its financial position or operations.
Confidence: HIGH
What changedThe board dropped the resolutions for a 67.44% stake acquisition via preferential allotment from the AGM notice to rework the transaction structure.
Why it mattersA controlling acquisition of an entity via share swap would impact equity dilution and related-party transaction exposure for a company with a market cap of ₹135 Cr.
Shares proposed for acquisition: 1,36,24,172Target equity stake: 67.44%Target entity: Archit Life Science LimitedAGM date: 30th September, 2026
📅 Short termRemoves immediate dilution and related-party transaction voting from the upcoming AGM while awaiting restructured terms.
📈 Long termThe structural expansion into Archit Life Science remains pending until the company presents a restructured acquisition proposal.
⚠ Risk flags
- Related-party transaction restructuring
- Uncertainty around future equity dilution terms
Key Highlights
Withdrew proposal to acquire 1,36,24,172 equity shares representing 67.44% of Archit Life Science Limited
Withdrew proposed preferential share allotment (other than cash) and increase in authorized share capital
Application for in-principle approval with BSE was in process prior to withdrawal
Withdrawal decided with a view to restructuring the proposed related-party transaction ahead of the September 30, 2026 AGM
👀 What to Watch
Track future board announcements regarding the revised deal terms and valuation structure for the Archit Life Science acquisition.
Archit Organosys Q1 Net Profit Drops 29% YoY to ₹1.45 Cr Despite 11.7% Revenue Growth
Archit Organosys reported a mixed performance for Q1 FY27, with revenue from operations growing 11.7% YoY to ₹37.08 Cr. However, net profit declined significantly by 28.9% YoY to ₹1.45 Cr, down from ₹2.04 Cr in the same quarter last year. This profit compression was largely driven by a 41% surge in 'Other Expenses' and a 25% increase in power and fuel costs. Sequentially, while revenue remained relatively flat (up 1.6%), net profit fell 28.4% from ₹2.02 Cr in Q4 FY26.
Confidence: HIGH
What changedThe company has released its unaudited financial results for the first quarter of FY27, showing a disconnect between top-line growth and bottom-line profitability.
Why it mattersFor a micro-cap company with a ₹125 Cr market cap, the significant margin contraction (Net Profit margin falling from ~6.1% to ~3.9% YoY) is a concern, especially given the already low ROCE of 4%.
Revenue (Q1 FY27): ₹37.08 CrNet Profit (Q1 FY27): ₹1.45 CrYoY Revenue Growth: 11.7%YoY Net Profit Growth: -28.9%Other Expenses: ₹5.20 CrEPS (Q1 FY27): ₹0.71
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the sharp decline in profitability and EPS despite revenue growth.
📈 Long termThe long-term outlook remains cautious unless the company can demonstrate structural improvements in its operating margins and ROCE within the commodity chemicals segment.
⚠ Risk flags
- Significant margin contraction
- Rising operational costs (Other Expenses and Power/Fuel)
- High P/E ratio (38.2) relative to low ROCE (4%)
Key Highlights
Revenue from operations increased to ₹37.08 Cr in Q1 FY27 from ₹33.20 Cr in Q1 FY26.
Net profit for the quarter fell to ₹1.45 Cr compared to ₹2.04 Cr in the year-ago period.
Other expenses rose sharply by 41% YoY to ₹5.20 Cr from ₹3.69 Cr.
Power and fuel costs increased 25% YoY to ₹1.28 Cr.
Basic and Diluted EPS decreased to ₹0.71 from ₹0.99 in the corresponding previous quarter.
👀 What to Watch
Investors should monitor the company's ability to pass on rising operational costs (power and other expenses) to customers to protect margins in future quarters.
Archit Organosys Q1 PAT drops 29% YoY to ₹1.45 Cr despite 12% revenue growth
Archit Organosys reported a mixed performance for Q1 FY27, with revenue from operations growing 11.7% YoY to ₹37.08 Cr. However, Net Profit declined significantly by 28.9% YoY to ₹1.45 Cr, down from ₹2.04 Cr in the same period last year. This profitability squeeze was driven by a 41% surge in 'Other Expenses' and higher power and fuel costs. The quarterly EPS consequently fell to ₹0.71 from ₹0.99 YoY.
Confidence: HIGH
What changedThe company released its unaudited financial results for the quarter ended June 30, 2026, showing a disconnect between top-line growth and bottom-line performance.
Why it mattersThe results highlight significant operational cost pressures, particularly in energy and miscellaneous expenses, which are eroding the company's already thin margins (TTM OPM 5.6%).
Revenue (Q1 FY27): ₹37.08 CrNet Profit (Q1 FY27): ₹1.45 CrYoY Revenue Growth: 11.7%YoY PAT Growth: -28.9%Q1 Revenue vs TTM Revenue: 32.8%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the sharp decline in profitability and margin contraction.
📈 Long termThe long-term outlook depends on the company's ability to scale revenue while managing volatile input and operational costs; the current ROCE of 4% remains a concern for capital efficiency.
⚠ Risk flags
- Significant margin contraction
- Rising operational costs (Other Expenses and Power/Fuel)
- High sensitivity to commodity chemical pricing
Key Highlights
Revenue from operations increased to ₹37.08 Cr from ₹33.20 Cr in the year-ago quarter.
Net Profit for the quarter stood at ₹1.45 Cr, a decline from ₹2.04 Cr in Q1 FY26.
Other expenses rose sharply to ₹5.20 Cr compared to ₹3.69 Cr in the previous year's corresponding quarter.
Power and fuel costs increased to ₹1.28 Cr from ₹1.03 Cr YoY.
Profit Before Tax (PBT) margin contracted to 5.4% from 8.9% in the year-ago period.
👀 What to Watch
Investors should monitor the trend in 'Other Expenses' and energy costs to determine if the current margin compression is structural or temporary. The company's ability to pass on cost increases in the commodity chemicals segment remains a key factor to watch in the next quarterly results.
